Federal Register Notice: FDA has determined the regulatory review period for Pfizer’s Xeljanz (tofacitinib citrate) is 3,947 days for extending a patent that claims the human drug product. Xeljanz is indicated for treating adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. To view this notice, click here.
